2,4-Diphenyl-6-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3,5-triazine

We are 2,4-Diphenyl-6-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3,5-triazine CAS:1219956-23-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2,4-Diphenyl-6-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3,5-triazine
CAS.NO:1219956-23-6
Synonyms:1,3,5-Triazine, 2,4-diphenyl-6-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-
Molecular Formula:C27H26BN3O2
Molecular Weight:435.32500
 
Specification:
Appearance:White powder
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates

2,4-Diphenyl-6-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3,5-triazine


Related News: It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance.59-49-4 With the improvement of domestic GMP management level, the increase of process development capabilities and international certification experience, China has already possessed the conditions for developing characteristic APIs.84449-80-9 Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined.p-Anisaldehyde Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.Jo Soden, Co-managing Director of Retrogenix, said “We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant’s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”

Related Products
Product Name
5,7-Dihydro-2-methylthieno[3,4-d]pyrimidine View Details
1,2-Dibromoethane View Details
3′-Deoxy-3′-fluoro Thymidine View Details
N,N-Dimethylpropionamide manufacturer CAS:20679-58-7 2-Butene-1,4-diol bis(bromoacetate) ester manufacturer 1-Bromo-3,3-Dimethyl-Butane manufacturer oleoyl ethanolamide manufacturer Fmoc-D-thiazolidine-4-carboxylic acid manufacturer